New Study: PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2023

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregular and often abnormally fast heart rate. Various therapeutic options are available to treat patients with AF, and most patients will receive some form of antithrombotic therapy, a heart rate control agent, and potentially, an antiarrhythmic drug for rhythm control.

All sectors of the AF market have historically been saturated with generics, with the vitamin K antagonists such as warfarin playing an important role in stroke prevention in AF. However, since 2010, and the launch of the first of the new oral anticoagulants (NOACs), a shift in the treatment of patients with AF has occurred. The NOACs offer a significant advancement in anticoagulation and their continued uptake will be the main driver of growth in the AF market over the next 10 years.

Full Report Details at
- http://www.fastmr.com/prod/998607_pharmapoint_atrial.aspx?afid=301

In contrast, despite a great unmet need for safer antiarrhythmic drugs, developments in this field are expected to be much slower. Two potential antiarrhythmic drugs are in late-stage development and are forecast to enter the market within the next decade: Gilead's ranolazine/dronedarone and ChanRx's vanoxerine.

Highlights

Key Questions Answered

* The anticoagulant market for stroke prevention in AF has become increasingly crowded. How will the drug treatment landscape for AF change? Which of the NOACs will become the market leader over the next ten years? What are the key drivers and barriers to this change?
* The AF market is marked by the presence of a number of unmet needs. What are the main unmet needs in the treatment of AF? Will the drugs under development fulfil the unmet needs of the AF market?
* Will any of the late-stage antiarrhythmic drugs make a significant impact on the AF market? Which of these drugs will have the highest peak sales at the end of the forecast period, and why?

Key Findings

* The major driver for the growth of the AF market will be the continued uptake of the NOACs for the prevention of stroke in patients with AF. Due to the advances that the NOACs provide in terms of improved safety and the lack of a need for routine monitoring, NOAC uptake will continue to increase, taking market share away from vitamin K antagonists, such as warfarin.
* The second major driver will be the approval and launch of the first antidotes for the NOACs, which will alleviate physician and patient concerns regarding a lack of a reversal agent in the event of uncontrolled bleeding, and will increase overall uptake.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Insomnia - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023